NCT03047616已完成不适用
A Pilot Study to Develop Predictive Biomarkers for the Response to Immunotherapy in Lung Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 88
- 试验地点
- 1
- 主要终点
- the correlation between markers identified in the blood and in the primary tumor.
研究概览
简要总结
Several immune checkpoint inhibitors targeting the PD-1 pathway have been developed with clinical trials showing an approximately 20% durable response in unselected patients with advanced non-small cell lung cancer (NSCLC). At the moment, no clear biomarker exists to accurately predict anti-PD1/PDL1 tumor responsiveness. The goal of this study is to broadly discover and evaluate the utility of blood based biomarkers for use in measuring and predicting response to immunotherapy in patients with lung cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Advanced Metastatic NSCLC
- •Scheduled to initiate an immune checkpoint inhibitor
- •Age >= 18 years
- •Able to provide informed consent
排除标准
- •Other, unrelated, concomitant active, invasive malignancy
结局指标
主要结局
the correlation between markers identified in the blood and in the primary tumor.
时间窗: 5 years
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell CarcinomaRenal Cell CarcinomaNCT05705583Zhejiang Cancer Hospital100
已完成
不适用
A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC PatientsNon -Small Cell Lung CancerNCT03486119Yonsei University60
已完成
不适用
A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC PatientsNon Small Cell Lung CancerNCT04312308Yonsei University100
已完成
1 期
PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast CancerBreast Neoplasm Malignant FemaleAdvanced Breast CancerNCT05812326Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University15
已完成
2 期
Immunotherapy in Patient With Poor General ConditionNon-small Cell Lung Cancer Stage IVNCT04108026Intergroupe Francophone de Cancerologie Thoracique50